Key result
Digoxin-enhanced ionizable liposomes attenuate doxorubicin cardiotoxicity while boosting efficacy in hepatocellular carcinoma.
Why the study?
Doxorubicin-induced cardiotoxicity remains a serious clinical complication despite liposomal encapsulation improving circulation and therapeutic efficacy.
Does doxorubicin delivery by ionizable liposomes with digoxin as the fifth component attenuate cardiotoxicity and enhance therapeutic efficacy in hepatocellular carcinoma models?
Does doxorubicin delivery by ionizable liposomes with digoxin as the fifth component attenuate cardiotoxicity and enhance therapeutic efficacy in hepatocellular carcinoma models?
A novel ionizable liposomal formulation of doxorubicin incorporating digoxin aims to reduce the clinical challenge of doxorubicin-induced cardiotoxicity while maintaining or enhancing anti-tumor efficacy.
Does not support clinical adoption in HCC; leaves open translation of digoxin-liposomes beyond preclinical models.
Dox-induced cardiotoxicity is a challenge in its clinical use. Although liposomal encapsulation of Dox improves its circulation and therapeutic efficacy, cardiotoxicity of Dox remains to be a serious clinical complication,...
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question. Doxorubicin delivered by ionizable liposomes with digoxin as a fifth component attenuated cardiotoxicity and enhanced therapeutic efficacy against hepatocellular carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: